The pitch sounds almost too convenient: a diagnostic test that delivers PCR-level accuracy for Lyme disease, runs on your smartphone, requires no refrigeration during shipping, and spits out results in half an hour. Yet Paris-based En Carta Diagnostics has convinced investors—and, perhaps more tellingly, U.S. regulators—that its freeze-dried molecular sensors might actually pull it off.
The two-year-old startup disclosed in July 2026 that it had closed the first €5 million (roughly $5.5 million) of what it's calling a seed round, money earmarked to commercialize diagnostic tests for Lyme disease and sexually transmitted infections. The announcement came with an unusual credential for such a young European company: FDA Breakthrough Device Designation for its flagship Lyme test, a regulatory nod typically reserved for technologies addressing serious unmet medical needs.
That designation doesn't guarantee approval—as industry experts regularly caution. But it does signal the agency sees promise—or at least enough potential—to warrant an accelerated review pathway.
Following the Money
The financing structure itself reveals something about En Carta's stage and standing. Of the €5 million, €3 million came as equity led by Blue Forest Ventures, with Ring Capital joining alongside earlier backers CentraleSupélec Venture and 50 Partners Health, plus a handful of unnamed business angels. The remaining €2 million arrived as non-dilutive support from Bpifrance, France's public investment bank, which tends to back companies it believes have export potential.
Calling this a "first closing" suggests more capital may be in the works—a common structure when investors want to see certain milestones hit before committing the full amount. En Carta had previously raised €1.5 million in a pre-seed round reportedly led by CentraleSupélec Venture, though the precise timing of that earlier raise remains somewhat murky in public filings.
For a company with around a dozen employees working out of the Paris Biotech Santé incubator, it's a respectable war chest. Whether it's enough to navigate the expensive, drawn-out world of diagnostics commercialization is another question.
The Science Behind the Claim
At the heart of En Carta's pitch is a platform built around freeze-dried synthetic biology sensors embedded in porous materials. The technical jargon translates to something more practical: a test that doesn't need refrigerated shipping and can allegedly match the accuracy of polymerase chain reaction (PCR) tests, the gold standard for molecular diagnostics.
The company's EC Pocket Lyme test is designed to be used at the site of a tick bite—ideally outdoors, far from a lab—with a smartphone providing the processing power. En Carta claims 98% accuracy against PCR benchmarks, though this accuracy claim has not been validated in independent peer-reviewed studies. Until it is, it remains a company assertion, not settled science.
Lyme isn't the only target. En Carta announced a partnership with AAZ, a French diagnostics firm, to develop tests for chlamydia and gonorrhea. The logic is similar: bring lab-quality molecular testing to decentralized settings where traditional infrastructure doesn't exist or can't easily reach. Think rural clinics, outdoor festivals, or developing markets where cold-chain logistics collapse in the heat.
It's an appealing vision. The challenge is execution.
Regulatory Pathways and Clinical Hurdles
According to the company's public communications, the FDA granted Breakthrough Device Designation on January 28, 2026. What's clearer is that the company has engaged with U.S. regulators in recent months, including at least one in-person meeting in Washington, based on LinkedIn posts from the team.
Clinical validation, meanwhile, is proceeding on two fronts. En Carta recruited participants for a study at Boston University's Clinical Testing Lab, focusing on a microneedle-based sampling device for early Lyme detection. A second trial is said to be running in Białystok, Poland, though primary documentation from the Polish institution proved elusive in publicly available sources—a not-uncommon issue with early-stage biotech studies that haven't yet published results.
The dual-continent approach makes strategic sense. The U.S. market is enormous, but European regulatory approval can sometimes move faster, and demonstrating real-world utility in both markets strengthens the eventual commercial story.
A Crowded, Complicated Field
En Carta enters a point-of-care molecular diagnostics market that Grand View Research pegs at about $9.28 billion as of this year, with growth expected to continue at a steady, if unspectacular, mid-single-digit clip through 2033. Lyme disease alone represents a significant opportunity—the CDC counted 62,551 cases in 2022 (the most recent year for which comprehensive data is available) under a revised definition, up 68.5% from prior baseline averages. Some claims-based estimates put annual diagnoses and treatments closer to 476,000 in the U.S. alone.
But opportunity has drawn competition. Sherlock Biosciences, flush with an $80 million Series B from 2020, is developing CRISPR-based diagnostics that include power-free STI tests. Visby Medical pursued portable PCR for both STIs and respiratory infections, though it discontinued its professional point-of-care line last September, pivoting instead toward consumer over-the-counter products—a strategic retreat that may hint at the challenges of selling into clinical workflows. Mammoth Biosciences also competes in the CRISPR diagnostics arena, though the company has increasingly tilted toward therapeutics in recent years.
The market, in other words, is both large and littered with pivots.
The Road Ahead
With fresh capital in hand, En Carta is now tasked with moving from concept to commercial reality. That means navigating regulatory submissions, scaling manufacturing for products that rely on freeze-dried biology (not exactly a plug-and-play process), and convincing clinicians to trust smartphone-powered tests over established lab workflows.
The company was founded in April 2022 by CEO Guillaume Horréard and biologist Dr. Margot Karlikow. It's participated in accelerators including Creative Destruction Lab Paris and PC'UP at ESPCI Paris, and earned a spot on Challenges magazine's "100 Start-ups Where to Invest" list last April—the kind of accolade that helps with fundraising but doesn't pay bills.
Marc Julien, a former executive at diabetes management company Diabeloop, joined the team recently, a hire that signals En Carta is preparing for the messy work of commercialization: distribution deals, reimbursement negotiations, customer support infrastructure.
Perhaps the hardest test of all, though, isn't regulatory or technical. It's convincing people that diagnostics belong in pockets, not just labs—a shift in clinical practice that's proven stubbornly difficult for even well-funded competitors. En Carta has the regulatory green light to try. Whether the market is ready to follow is the question that will define its next chapter.
